{"id":13666,"date":"2026-02-23T18:53:32","date_gmt":"2026-02-23T14:53:32","guid":{"rendered":"https:\/\/medscriptum.org\/?p=13666"},"modified":"2026-02-23T18:53:54","modified_gmt":"2026-02-23T14:53:54","slug":"2026-aha-acc-guideline-for-the-management-of-acute-pulmonary-embolism","status":"publish","type":"post","link":"https:\/\/medscriptum.org\/en\/2026-aha-acc-guideline-for-the-management-of-acute-pulmonary-embolism\/","title":{"rendered":"2026 AHA\/ACC Guideline for the Management of Acute Pulmonary Embolism"},"content":{"rendered":"

The 2026 AHA\/ACC Guideline for the management of acute pulmonary embolism (PE) in adults represents the first complete,<\/span> fundamental document in this field.<\/span> The mentioned guideline was created as a result of close collaboration between the American Heart Association,<\/span> the American College of Cardiology,<\/span> and other leading professional unions.<\/span><\/p>\n

The recommendations published in the journals Circulation and JACC are based on a patient-oriented approach and encompass the full clinical path (from the manifestation of primary symptoms to long-term post-hospital monitoring).<\/span> A key element of the guideline represents a new,<\/span> five-level system of clinical categories (A-E),<\/span> which,<\/span> in terms of determining the prognosis and assessing risks,<\/span> is characterized by significantly higher accuracy compared to previously existing methods (Hestia<\/a> or sPESI<\/a>).<\/span><\/p>\n

The document bases the treatment strategy on three fundamental directions,<\/span> which implies the coordinated work of multidisciplinary PERT teams to make critical decisions,<\/span> the recognition of direct-acting anticoagulants (DOAC) as a therapeutic priority,<\/span> and the prevention of chronic complications (CTEPD).<\/span><\/p>\n

\"\"
AHA|ASA Journals<\/figcaption><\/figure>\n

Determination of Risk and Initial Clinical Evaluation<\/strong><\/p>\n

\"\"
AHA|ASA Journals<\/figcaption><\/figure>\n

The central part of the guideline represents a clinical classification system, which determines the patient’s status through a synthetic analysis of hemodynamic data, the state of the right ventricle, biomarkers, and the clinical picture. This methodological approach helps the doctor in selecting the hospitalization, the quality of observation, and the therapeutic tactics.<\/p>\n

Categories A and B (Low risk): The mentioned group unites asymptomatic or hemodynamically stable patients. Their treatment is often limited to the prescription of direct-acting oral anticoagulants (DOAC) and direct discharge from the emergency department.<\/p>\n

Categories C1-C3 (Intermediate risk): Patients with normal arterial pressure, though with pronounced right ventricular strain or pathological changes in biomarkers, fall into this group. In order to avoid a possible worsening of the condition, they require mandatory hospitalization and constant monitoring.<\/p>\n

Categories D and E (High risk): The given classification encompasses critical conditions\u2014impending shock (D) and persistent hypotension or decompensated shock (E). It is noteworthy that the 30-day mortality rate in category E exceeds 15%.<\/p>\n

\"\"
AHA|ASA Journals<\/figcaption><\/figure>\n

The diagnostic process is maximally optimized through the combined use of D-dimer (in low-risk groups), computed tomographic angiography (CTPA), and echocardiography. While managing patients of the C-E category, for the effective coordination of the treatment tactics, the operational involvement of a multidisciplinary team (PERT) is assigned decisive importance.<\/p>\n

Hemodynamic Stabilization and Supportive Therapeutic Measures<\/b><\/h5>\n

Due to the sharp decrease in the function of the right ventricle, the hemodynamic balance in patients with pulmonary artery thromboembolism is critically disturbed.<\/p>\n

The use of sedative means or the process of intubation, through the weakening of compensatory tachycardia and systemic vascular resistance (SVR), significantly disturbs hemodynamic stability. The mentioned interventions are characterized by a high risk of total cardiovascular collapse, which is also evidenced by the high (19-28%) rate of cardiac arrest during the induction period.<\/p>\n

Accordingly, it is necessary to minimize the doses of preparations and to have readiness for the use of vasopressors (the first-choice choice is noradrenaline), inotropes (dobutamine), or veno-arterial extracorporeal membrane oxygenation (VA-ECMO). During E2 category shock, the use of VA-ECMO ensures the offloading of the right ventricle and the maintenance of perfusion, which is also confirmed by data from international registries.<\/p>\n

During the management of hypoxemia, a high-flow nasal cannula (HFNC) exhibits better results compared to standard oxygen therapy. Despite the fact that specific data regarding non-invasive ventilation are small, it is still considered as a supportive means during general respiratory failure. Upon the start of anticoagulation therapy, the early mobilization and activation of the patient, compared to a long-term bed-rest regime, significantly reduces the probability of the recurrence of venous thromboembolism.<\/p>\n

Anticoagulation Therapy<\/b><\/h5>\n

Taking into account the less risk of bleeding and the convenience of use, direct-acting oral anticoagulants (DOAC), such as apixaban and rivaroxaban, represent the first-line (Class 1) choice of therapy compared to Vitamin K antagonists (VKA).<\/p>\n

Among injectable preparations, preference is given to low-molecular-weight heparin (LMWH), although during a severe disturbance of kidney function or critical instability, when the rapid cessation of the anticoagulation effect is necessary, unfractionated heparin is still used.<\/p>\n

The treatment scheme at the initial stage implies loading with high doses of apixaban and rivaroxaban. While the selection of the duration of therapy is decided individually, according to the risk of the repetition of the disease: if the thromboembolism was caused by a temporary factor (surgical intervention), a 3-6 month course is completely sufficient, while during idiopathic cases, due to the high (30-40% in 10 years) statistical indicator of recurrence, patients require medicinal protection for a long time.<\/p>\n

In the management of thromboembolism developed against the background of oncological pathologies, the choice again stops on DOACs and LMWH. In the case where the disease repeats despite the anticoagulation treatment, a detailed diagnostics of the condition (CTPA\/VQ scan) becomes necessary, to specify the causative reasons (e.g., violation of the treatment regime, oncological process, antiphospholipid syndrome) and to modify the therapy in favor of low-molecular-weight heparin.<\/p>\n

\"\"
AHA|ASA Journals<\/figcaption><\/figure>\n
Reperfusion Therapy and Interventional Management<\/b><\/h5>\n

In patients with high risk, the decision is made on the basis of a detailed analysis of the probability of bleeding and the expected clinical benefit. Despite the high therapeutic effectiveness of systemic thrombolytic therapy (Alteplase 100 mg), it is followed by an increased risk of serious hemorrhagic complications, including intracranial bleeding.<\/p>\n

Low-dosed thrombolytic therapy (25-50 mg) is considered as a safe and effective strategy for restoring the function of the right ventricle. At the same time, catheter technologies (CDT) give the possibility of achieving hemodynamic stability against the background of minimal risks, which determines their priority in the process of managing complex clinical cases.<\/p>\n

Mechanical thrombectomy (MT) represents a highly effective alternative for patients of various severity (E1 and D1-2), while surgical embolectomy performed in high-profile clinics ensures almost total survival (>97%) of patients.<\/p>\n

Extracorporeal membrane oxygenation (VA-ECMO) during an extremely severe condition requires necessary anticoagulation support. The existence of a \u201cmobile thrombus\u201d is especially dangerous, due to which thrombolytic therapy at this time is considered as a priority compared to ordinary anticoagulation. While the use of cava-filters is justified only during strict contraindications, moreover, their timely removal (within the scope of 54 days) must be implemented with the protection of special rules.<\/p>\n

Post-Hospital Monitoring and Preventive Strategies<\/b><\/h5>\n

The post-hospital stage of patient management includes an early ambulatory visit in the very first week and a repeated assessment at the head of three months. The latter is critically important for the correction of the anticoagulation strategy, the study of thrombophilia, and targeted oncological screening. Practice shows that oncological vigilance should primarily be based on physical examination and anamnesis data, since large-scale radiological screening in this case is less informative.<\/p>\n

In the existence of chronic shortness of breath, which is noted in a fairly large part of patients, a complex diagnostic approach (V\/Q scanning, exercise tests, and echocardiography) is used to exclude CTEPD (Chronic Thromboembolic Pulmonary Disease).<\/p>\n

\"\"
AHA|ASA Journals<\/figcaption><\/figure>\n

At the same time, for full-fledged rehabilitation, an approach oriented toward mental health is decisive, which serves the management of post-traumatic anxiety and the improvement of the patient’s quality of life.<\/p>\n

In the case of pregnancy, hemodynamic safety is achieved by the use of low-molecular-weight heparins and multidisciplinary supervision. To reduce the risk of gynecological hemorrhagic complications, the use of apixaban or dabigatran is a priority, while the prevention of recurrence in the process of a long journey implies the synthesis of compression knitwear and adequate pharmacoprophylaxis.<\/p>\n

Future Perspectives<\/b><\/h5>\n

Despite the achievements of modern medicine, certain aspects in the management of pulmonary artery thromboembolism still require in-depth research. The practical validation of the AHA\/ACC classification, the comparative analysis of the effectiveness of various invasive interventions, and the development of thrombolytic agents with an improved safety profile are considered as priority directions of future scientific search.<\/p>\n

In the future, research will also focus on the dynamics of chronic forms, the integration of artificial intelligence into the diagnostic process, and the adaptation of medical protocols in conditions of limited resources. Taking into account the pregnancy or the hormonal background, the refinement of preventive measures and the introduction of such complex manipulations as PTE and BPA in high-tech clinics significantly increases the chances of patient survival.<\/p>\n

The given document, which serves the introduction of individual approaches to treatment, through the use of multidisciplinary cooperation and modern medicinal therapy, gives a real possibility of reducing the lethality indicator to a minimum.<\/p>\n

Source:\u00a0 AHA|ASA Journals\u00a0<\/a><\/p>\n



<\/p>\n","protected":false},"excerpt":{"rendered":"

The 2026 AHA\/ACC Guideline for the management of acute pulmonary embolism (PE) in adults represents the first complete, fundamental document in this field. The mentioned guideline was created as a result of close collaboration between the American Heart Association, the American College of Cardiology, and other leading professional unions. The recommendations published in the journals […]<\/p>\n","protected":false},"author":5,"featured_media":13668,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1596],"tags":[4503,3224,4505],"class_list":["post-13666","post","type-post","status-publish","format-standard","has-post-thumbnail","category-internal-medicine","tag-aha-acc","tag-guidline","tag-pe"],"acf":[],"_links":{"self":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/13666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/comments?post=13666"}],"version-history":[{"count":2,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/13666\/revisions"}],"predecessor-version":[{"id":13683,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/13666\/revisions\/13683"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/media\/13668"}],"wp:attachment":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/media?parent=13666"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/categories?post=13666"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/tags?post=13666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}